Hims & Hers Health (NYSE:HIMS) Shares Down 7.3% – Should You Sell?

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price fell 7.3% during trading on Tuesday . The company traded as low as $32.31 and last traded at $32.16. 4,273,332 shares traded hands during trading, a decline of 68% from the average session volume of 13,503,571 shares. The stock had previously closed at $34.69.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on HIMS shares. Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Truist Financial increased their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research note on Wednesday, February 26th. Finally, Piper Sandler boosted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Stock Down 7.8 %

The stock has a fifty day moving average of $38.64 and a two-hundred day moving average of $28.37. The stock has a market cap of $7.11 billion, a price-to-earnings ratio of 72.63 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $24.44, for a total value of $283,039.64. Following the completion of the transaction, the chief financial officer now owns 118,077 shares of the company’s stock, valued at approximately $2,885,801.88. This represents a 8.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Michael Chi sold 17,303 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at $9,319,952.14. This represents a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 890,592 shares of company stock valued at $31,677,291. Corporate insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently modified their holdings of HIMS. SlateStone Wealth LLC increased its holdings in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. raised its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after purchasing an additional 628 shares during the last quarter. Cim LLC boosted its holdings in Hims & Hers Health by 1.0% in the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock worth $1,738,000 after purchasing an additional 694 shares during the period. Finally, Quest Partners LLC increased its stake in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.